Lv1
60 积分 2023-07-14 加入
Drugging p53: Barriers, Criteria, and Prospects
2天前
已完结
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia
1个月前
已完结
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor
5个月前
已完结
Computational benchmarking of putative KIFC1 inhibitors
5个月前
已完结
Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy
5个月前
已完结
Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors
5个月前
已完结
Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor
5个月前
已完结
DCAF16-Based Covalent Handle for the Rational Design of Monovalent Degraders
6个月前
已完结
Oxetanes in Drug Discovery Campaigns
7个月前
已完结
Systematic Study of the Glutathione (GSH) Reactivity of N-Arylacrylamides: 1. Effects of Aryl Substitution
9个月前
已完结
皖公网安备34019202002308
